drugset / Trial / NCT00524186

Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer

NCT00524186

Phase 1 Terminated 23 enrolled Roswell Park Cancer Institute Pfizer · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sunitinib together with combination chemotherapy may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of sunitinib when given together with irinotecan, fluorouracil, and leucovorin in treating patients with advanced stomach cancer or gastroesophageal cancer.

Timeline

Start
2007-05
Primary completion
2013-08
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule Intravenous
Subject Sunitinib Small molecule Oral
Background Leucovorin Small molecule Intravenous
Background fluorouracil Small molecule Intravenous